SCHEMBL3247669

SCHEMBL3247669

CCOC(=O)c1c[nH]c2c(=O)[nH]c3ccc(-c4ccc5[nH]ccc5c4)cc3c12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 3/20 0.48
JAK3 P52333 3/20 0.48
NPC1 O15118 1/20 0.44
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C19 P33261 1/20 0.43
MAOA P21397 1/20 0.43
GABRA1 P14867 2/20 0.43
GABRB2 P47870 2/20 0.43
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 2/20 0.42
HPGD P15428 2/20 0.42
GABRB1 P18505 1/20 0.42
GABRA3 P34903 1/20 0.42
CLEC4M Q9H2X3 1/20 0.42
CCNC P24863 1/20 0.39
CDK8 P49336 1/20 0.39
MMP2 P08253 1/20 0.39
MMP13 P45452 1/20 0.39
MMP14 P50281 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3252757 0.87 NPC1 (0.51) JAK2JAK3NPC1CYP1A2CYP3A4
SCHEMBL3249649 0.86 JAK2 (0.50) JAK2JAK3NPC1CYP1A2CYP3A4
SCHEMBL3250598 0.85 JAK2 (0.50) JAK2JAK3NPC1CYP1A2CYP3A4
SCHEMBL3244562 0.84 CCNC (0.38) JAK2JAK3NPC1CYP1A2CYP3A4
SCHEMBL3245574 0.84 NPC1 (0.43) NPC1CYP1A2HSD17B10
SCHEMBL3250086 0.84 JAK2 (0.52) JAK2JAK3NPC1CYP1A2CYP3A4
SCHEMBL3252802 0.84 GABRA1 (0.43) JAK2JAK3NPC1CYP1A2CYP3A4
SCHEMBL3247523 0.83 CLEC4M (0.46) JAK2JAK3NPC1CYP1A2CYP3A4
SCHEMBL3252056 0.83 NPC1 (0.43) JAK2JAK3NPC1CYP1A2CYP3A4
SCHEMBL3249012 0.83 NPC1 (0.46) JAK2JAK3NPC1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1899335-B1 PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS PF MEDICAMENT (FR) 2010-05-19 EP claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 JAK2 70/4885JAK3 171/4885NPC1 3366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.